Secondary Hypogonadism and Effects of Testosterone Replacement Therapy on Cardiovascular Events
Authors' conclusion
TRT does not appear to increase risk of MACE in those with SHG related to pituitary disorders. Untreated SHG appears to convey increased risk of mortality though these patients were older and more comorbid.
Study context
- Population
- Male patients with nonfunctioning pituitary adenomas and prolactinomas, with and without secondary hypogonadism (SHG)
- Participants
- 408 patients
- Exposure
- Testosterone replacement therapy (TRT)-treated SHG vs untreated SHG vs no SHG
- TRT-treated SHGn = 214
- Untreated SHGn = 44
- No SHGn = 150reference
- Outcome
- MACE:
- Stroke
- MI
- Mortality
- Follow-up
- Median 8.1 years (IQR 3.3-14.1)
Main finding
As reported in the abstract
MACE
Observational data: associations, not effects.
Further findings
- Increased risk of mortality in untreated SHG vs both TRT-treated SHG and no SHG
Original publication
Secondary Hypogonadism and Effects of Testosterone Replacement Therapy on Cardiovascular Events. J Clin Endocrinol Metab. Published 18 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →